^
    7ms
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)
    10ms
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)
    over1year
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=107, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jun 2023 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)
    3years
    ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies (ASH 2021)
    Safety and efficacy data will be analyzed using summary statistics and Kaplan Meier estimates as appropriate; PK parameters will be estimated using noncompartmental methods. ARC-12 is actively recruiting at sites in the United States (NCT04772989).
    Clinical • P1 data
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)
    over3years
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=154, Recruiting, Arcus Biosciences, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)
    almost4years
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=154, Not yet recruiting, Arcus Biosciences, Inc.
    Clinical • New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • ralzapastotug (AB308)